kinect-HD logo


What is it

KINECT-HD is a Phase 3, randomized, double-blind, placebo-controlled study


To evaluate the safety, tolerability and efficacy of valbenazine in reducing the chorea symptom associated with Huntington's disease.



Neurocrine Biosciences, Inc


The experimental drug

It is called valbenazine (valbenazine tosylate, NBI-98854). Tt is a selective and active VMAT2 inhibitor studied for the treatment of chorea associated with Huntington's disease. The drug is currently on the market for the treatment of tardive dyskinesia, under the trade name INGREZZA.


Drug Administration

The drug is administered orally, one tablet per day  for 12 weeks  


Study location an number of participants 

46 HD Centres in US and Canada; 120 participants in total.



18 weeks, including a screening period, a drug versus placebo period, and a follow-up period. Participants will be required to participate in nine (9) visits during the study. A final check will be done two (2) weeks after stopping the drug or placebo, or at the end of the study.


Inclusion criteria

Age 18 - 75
Diagnosis of Huntington with manifest motor symptoms 

Starting date  

November 2019


Estimated ending date

Sptember 2021


Learn more on: